Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Lucía Pérez-Lamas, Juan Carlos Hernandez Boluda, Luis Felipe Casado Montero, Maria Teresa Gómez Casares, Rosa Ayala, Blanca Xicoy, Francisca Ferrer Marin, Guillermo Orti, Raquel De Paz Arias, Santiago Osorio Prendes, Raul Perez Lopez, Elvira Mora, Concepción Ruiz Nuño, Antonio Jimenez Velasco, Concepcion Boque, Magdalena Sierra Pacho, Joaquin Martinez Lopez, Valentin Garcia Gutierrez

Blood (2023) 142 (Supplement 1): 1795.

https://doi.org/10.1182/blood-2023-184989

Published: 2023

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

https://doi.org/10.1182/blood-2022-167453

Published: 2022

Journal Articles

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, Pilar Giraldo, Blanca Xicoy, Luis Felipe Casado, Fermin Sanchez-Guijo, Concepción Ruiz Nuño, Melania Moreno Vega, Alberto Alvarez-Larran, Araceli Salamanca Cuenca, Ana García-Noblejas, Ferran Vall-Llovera, Manuel Perez Encinas, Lucia Villalon, Natalia De las Heras, Sunil Lakhwani, Elena Ramila, Beatriz Cuevas, Raul Perez Lopez, Antonio Jiménez-Velasco, Ana Rosell, Angeles Escola, Maria Jose Fernández, Carmen Garcia-Hernandez, Carlos Cervero, Elvira Mora Casterá, Miguel Sagüés, Sara Suarez-Varela, Patricia Vélez, Patricia Carrascosa Mastell, Rocio Fé Bitaube, Luis Serrano, Montse Cortes, Juan Antonio Juan Vera Goñi, Juan Luis Steegmann, Juan Carlos Hernandez Boluda, Valle Gomez, Juan Manuel Alonso-Dominguez, Mercedes Colorado Araujo, Antonio Paz Coll, Valentín Garcia Gutierrez

Blood (2021) 138 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2021-150813

Published: 2021

Journal Articles

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-138690

Published: 2020

Journal Articles

Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION

Massimo Breccia, MD, Michael J. Mauro, MD, Elias Jabbour, MD, Giuseppe Saglio, MD PhD, Antonio Jiménez-Velasco, MD, Philipp D le Coutre, MD, Irene DeGutis, PharmD, Wasiulla Khan, PhD, Oumar Sy, PhD, Rene Swanink, Jorge E. Cortes, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-137636

Published: 2020

Journal Articles

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Massimo Breccia, MD, Jorge E. Cortes, MD, Neil P Shah, MD PhD, Giuseppe Saglio, MD, Antonio Jiménez-Velasco, MD, Philipp Le Coutre, MD, Alexander Brun, PharmD, Irene DeGutis, Sai Bathena, Oumar Sy, PhD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 4155.

https://doi.org/10.1182/blood-2019-121872

Published: 2019

Journal Articles

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, MD PhD, Antonio Jiménez-Velasco, MD, Sarah Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Yair Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin Regueira, MD, Jeffrey H. Lipton, MD PhD

Blood (2018) 132 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2018-99-116563

Published: 2018

Journal Articles

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, PhD, Antonio Jiménez-Velasco, MD, Sarah M Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin-Regueira, MD, Jeffrey H. Lipton, PhD MD FRCPC

Blood (2017) 130 (Supplement 1): 314.

https://doi.org/10.1182/blood.V130.Suppl_1.314.314

Published: 2017

Journal Articles

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Blood (2017) 130 (Supplement 1): 1624.

https://doi.org/10.1182/blood.V130.Suppl_1.1624.1624

Published: 2017

Journal Articles

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

Neil P. Shah, MD PhD, Ronald Paquette, MD, Martin C. Müller, MD, Susanne Saussele, MD, Valentin Garcìa-Gutiérrez, MD, Antonio Jiménez-Velasco, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Francois-Xavier Mahon, MD PhD, Delphine Rea, MD PhD, Patricia Martin-Regueira, MD, Milayna Subar, MD, Li Li, PhD, Jeffrey H. Lipton, MD PhD

Blood (2016) 128 (22): 1895.

https://doi.org/10.1182/blood.V128.22.1895.1895

Published: 2016

Journal Articles

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

Valentín García Gutiérrez, María Teresa Gómez-Casares, Jose Manuel Puerta, Juan Manuel Alonso, Santiago Osorio, Juan Carlos Hernández-Boluda, Rosa Collado, Maria Jose Ramirez, MD, Fatima Ibañez, MD, Maria Luisa Martin, Juan Diego Rodriguez, Carolina Martinez-Laperche, Montse Gomez, Viviana Fiallo, Redondo Sara, Alicia Rodriguez, Concepcion Ruiz, Juan Luis Steegmann, MD, Antonio Jiménez-Velasco, MD

Blood (2016) 128 (22): 1906.

https://doi.org/10.1182/blood.V128.22.1906.1906

Published: 2016

Journal Articles

A New Multiple Single-Nucleotide Polymorphisms Based Predictive Model for Grades III to IV and Extensive Graft Versus Host Disease after Identical HLA-Allogeneic Stem-Cell

Blood (2015) 126 (23): 921.

https://doi.org/10.1182/blood.V126.23.921.921

Published: 2015

Journal Articles

The Use of Imatinib with Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation Improves Survival of Philadelphia Positive Acute Lymphoblastic Leukemia in Adults

Josefina Perez-Nuñez, MD, Antonio Jimenez-Velasco, MD, Katy Hurst, MD, Manuel Barrios-Garcia, MD PhD, MJ Moreno, MD, Ana Isabel Heiniger Mazo, MD

Blood (2014) 124 (21): 3653.

https://doi.org/10.1182/blood.V124.21.3653.3653

Published: 2014

Journal Articles

Donor and Recipient Genotypes for Interleukin 1 Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation of Acute Graft Versus Host Disease after HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT)

Blood (2014) 124 (21): 666.

https://doi.org/10.1182/blood.V124.21.666.666

Published: 2014

Journal Articles

Donor Genotypes For Interleukin-17A Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation Of Complications After HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT)

Blood (2013) 122 (21): 4619.

https://doi.org/10.1182/blood.V122.21.4619.4619

Published: 2013

Journal Articles

A Gene Variant in IRF3 Impacts On the Clinical Outcome of Acute Myeloid Leukemia (AML) Patients Submitted to Allogeneic Stem Cell Transplantation (allo-SCT)

Beatriz Martin-Antonio, Ph.D., Maria Suarez-LLedo, Montserrat Arroyes, Francesc Fernandez-Avilés, Carmen Martinez, MD, Montserrat Rovira, Ildefonso Espigado, MD, PhD, David Gallardo, MD, PhD, Anna Bosch, Ismael Buno, PhD, Carolina Martinez-Laperche, PhD, Antonio Jimenez-Velasco, Rafael De La Camara, MD, Salut Brunet, Jose B. Nieto, Alvaro Urbano-Ispizua, MD/Ph.D

Blood (2012) 120 (21): 468.

https://doi.org/10.1182/blood.V120.21.468.468

Published: 2012

Journal Articles

-52G/A Gene Variant in the β-Defensin-1 ( DEBF1 ) Influences the Development of Severe Acute Graft Versus Host Disease (aGvHD) After Allogeneic Stem Cell Transplantation (Allo-SCT). Functional Association of This Variant with a Low Anti- Inflammatory Response

Beatriz Martin-Antonio, Damià Romero, David Gallardo, MD, PhD, Anna Bosch, Ildefonso Espigado, MD, PhD, Ismael Buno, Carolina Martinez-Laperche, Antonio Jimenez-Velasco, Rafael De La Camara, MD, Salut Brunet, Nieto B Jose, Jose Román, Maria Suarez-LLedo, Francesc Fernandez-Avilés, Carmen Martinez, Montserrat Rovira, Alvaro Urbano-Ispizua, MD

Blood (2011) 118 (21): 3052.

https://doi.org/10.1182/blood.V118.21.3052.3052

Published: 2011

Journal Articles

The Genotype in the Donor and Recipient for the Polymorphim −174 G/C of the IL-6 Influences the Outcome of HLA-Identical Related Stem Cell Transplantation,

Blood (2011) 118 (21): 4082.

https://doi.org/10.1182/blood.V118.21.4082.4082

Published: 2011

Journal Articles

CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors.

Arianne Pérez-García, Rafael De la Cámara, Jose Román-Gómez, Antonio Jiménez-Velasco, Maite Encuentra, Jose B. Nieto, Javier de la Rubia, Alvaro Urbano-Ispizúa, Salut Brunet, Arturo Iriondo, Marcos González, David Serrano, Ildefonso Espigado, Carlos Solano, Josep M. Ribera, Josep M. Pujal, Montserrat Hoyos, David Gallardo, the GVHD/Immunotherapy Committee of the Spanish Group of Hematopoietic Stem Cell Transplantation

Blood (2007) 110 (1): 461–467.

https://doi.org/10.1182/blood-2007-01-069781

Published: 2007

Includes: Supplemental data

Journal Articles

Improved Prediction of Acute Leukemia Relapse after Allogeneic SCT by Chimerism Analysis of Null Alleles and Indel Polymorphisms with Real-Time Quantitative PCR.

Antonio Jimenez-Velasco, MD, Manuel Barrios, MD, PhD, Jose Roman-Gomez, MD, PhD, German Navarro, PhD, Ismael Buño, PhD, Jose L. Diez-Martin, MD, PhD, Antonio Torres, MD, PhD, Ana I. Heiniger, MD

Blood (2004) 104 (11): 1650.

https://doi.org/10.1182/blood.V104.11.1650.1650

Published: 2004

NARROW

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

A New Multiple Single-Nucleotide Polymorphisms Based Predictive Model for Grades III to IV and Extensive Graft Versus Host Disease after Identical HLA-Allogeneic Stem-Cell

The Use of Imatinib with Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation Improves Survival of Philadelphia Positive Acute Lymphoblastic Leukemia in Adults

Donor and Recipient Genotypes for Interleukin 1 Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation of Acute Graft Versus Host Disease after HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT)

Donor Genotypes For Interleukin-17A Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation Of Complications After HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT)

A Gene Variant in IRF3 Impacts On the Clinical Outcome of Acute Myeloid Leukemia (AML) Patients Submitted to Allogeneic Stem Cell Transplantation (allo-SCT)

-52G/A Gene Variant in the β-Defensin-1 ( DEBF1 ) Influences the Development of Severe Acute Graft Versus Host Disease (aGvHD) After Allogeneic Stem Cell Transplantation (Allo-SCT). Functional Association of This Variant with a Low Anti- Inflammatory Response

The Genotype in the Donor and Recipient for the Polymorphim −174 G/C of the IL-6 Influences the Outcome of HLA-Identical Related Stem Cell Transplantation,

CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors.

Improved Prediction of Acute Leukemia Relapse after Allogeneic SCT by Chimerism Analysis of Null Alleles and Indel Polymorphisms with Real-Time Quantitative PCR.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only